Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts - 2The Best Cell phone Brands for Tech Aficionados
- 3'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more
- 4Shrewd Home Gadgets to Save Energy
- 5See tonight’s solar storm unfold across the world
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- Procter & Gamble changes Crest toothpaste packaging to address Texas AG fluoride concerns
- The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- The Response Uncovered: Disentangling the Secrets of the Universe
- The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- I thought I knew the night sky, but what I saw from the Canary Islands left me speechless
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
